[SCHEDULE 13G/A] RECURSION PHARMACEUTICALS, INC. Amended Passive Investment Disclosure

Rhea-AI Filing Summary

BlackRock, Inc. filed Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 37,821,797 Class A shares of Recursion Pharmaceuticals. The filing states this equals 7.2% of the Class A stock and shows 37,178,542 shares for which BlackRock has sole voting power. The signature is dated 04/24/2026 and the cover date is 03/31/2026.

Insights

Institutional Ownership Analyst

BlackRock reports a material passive stake of 7.2% in Recursion.

The filing lists 37,821,797 shares beneficially owned and a 7.2% ownership percentage in Class A common stock. The record shows sole voting power for 37,178,542 shares and sole dispositive power for 37,821,797 shares.

Institutional holdings at this scale are relevant to shareholder composition and potential voting outcomes; subsequent amendments or 13D filings would show any change in intent or activism.

Corporate Governance Specialist

Disclosure clarifies voting and dispositive authority across BlackRock business units.

The schedule notes that the figures reflect securities attributable to certain Reporting Business Units of BlackRock, not necessarily all BlackRock entities. Item 6 explains that various persons may have rights to dividends or proceeds without any single third party exceeding 5% individually.

Investors and issuers should track future amendments for any shifts in voting intent or coordination among holders; timing and motive are not specified here.

Key Figures

Beneficially owned shares: 37,821,797 shares Percent of class: 7.2% Sole voting power: 37,178,542 shares +3 more

6 metrics

Beneficially owned shares 37,821,797 shares Class A stock reported in Item 4

Percent of class 7.2% Percent of Class A stock reported in Item 4

Sole voting power 37,178,542 shares Item 4(i) sole power to vote

Sole dispositive power 37,821,797 shares Item 4(iii) sole power to dispose

Cover date 03/31/2026 Cover page date

Signature date 04/24/2026 Signature date by Spencer Fleming

Key Terms

Schedule 13G/A, Beneficially owned, Sole dispositive power, Reporting Business Units

4 terms

Schedule 13G/A regulatory

"Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned financial

"Amount beneficially owned: 37821797"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 37821797"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Reporting Business Units corporate

"securities beneficially owned by certain Reporting Business Units of BlackRock"

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

RECURSION PHARMACEUTICALS, INC.

(Name of Issuer)

Class A Stock

(Title of Class of Securities)

75629V104

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 75629V104

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 37,178,542.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 37,821,797.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

37,821,797.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.2 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: RECURSION PHARMACEUTICALS, INC.
(b)	Address of issuer's principal executive offices: 41 S RIO GRANDE STREET SALT LAKE CITY UT 84101
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Class A Stock
(e)	CUSIP No.: 75629V104
Item 4.	Ownership
(a)	Amount beneficially owned: 37821797
(b)	Percent of class: 7.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 37178542
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 37821797
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of RECURSION PHARMACEUTICALS, INC.. No one person's interest in the common stock of RECURSION PHARMACEUTICALS, INC. is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	04/24/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7

FAQ

What stake does BlackRock hold in Recursion Pharmaceuticals (RXRX)?

BlackRock reports beneficial ownership of 37,821,797 Class A shares, representing 7.2% of the Class A stock. The filing is an Amendment No. 4 to a Schedule 13G/A and cites a cover date of 03/31/2026.

How much voting power does BlackRock report on Recursion's shares?

BlackRock reports sole voting power for 37,178,542 shares. The Schedule 13G/A separates sole voting power and dispositive power as disclosed in Item 4 of the form.

Does the filing indicate BlackRock will control or direct other shareholders?

The filing states the holdings reflect certain Reporting Business Units and does not indicate control of other shareholders. Item 6 notes no single outside person holds over 5% of the shares listed.

When was the Schedule 13G/A amendment signed?

The schedule was signed by Spencer Fleming, Managing Director, with a signature date of 04/24/2026. The cover page shows the reporting date as 03/31/2026.

Does this Schedule 13G/A reveal BlackRock's investment intent?

The Schedule 13G/A lists passive beneficial ownership figures but does not state any change in investment intent. Amendment filings update ownership detail; intent is not explicitly described in the excerpt.